Malondialdehyde in benign prostate hypertrophy: a useful marker?
Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non-invasive biomar...
Saved in:
Main Authors: | Rosaria Alba Merendino, Francesco Salvo, Antonella Saija, Giuseppe Di Pasquale, Antonio Tomaino, Paola Lucia Minciullo, Giuseppe Fraccica, Sebastiano Gangemi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2003-01-01
|
Series: | Mediators of Inflammation |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/0962935031000097745 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil
by: Juan Manuel Palacios, et al.
Published: (2025-01-01) -
Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01) -
The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy
by: Ugo Giovanni Falagario, et al.
Published: (2025-01-01) -
Rauwolfia vomitoria- a promising medical plant for benign prostatic hyperplasia management; yet with challenges
by: George Awuku Asare, et al.
Published: (2025-02-01) -
Urology pathways for the primary care physician
by: J John
Published: (2024-04-01)